ANDA 76565, held by Teva Pharmaceutical Industries. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 76565 (Venlafaxine Hydrochloride), held by Teva Pharmaceutical Industries, was first approved by FDA on Jun 28, 2010, with 14 approved supplements and 0 published complete response letters.
Venlafaxine hydrochloride extended-release capsules are indicated in adults for the treatment of: Major Depressive Disorder (MDD) Generalized Anxiety Disorder (GAD) Social Anxiety Disorder (SAD) Panic Disorder (PD) Venlafaxine hydrochloride extended-release capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with: Major Depressive Disorder (MDD) Generalized Anxiety Disorder (GAD) Social Anxiety Disorder (SAD) Panic Disorder (PD)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 28, 2010 | Original application | Approved |
| Venlafaxine HydrochlorideEQ 37.5MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 75MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 150MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Aug 12, 2024 | Supplement 23Labeling · Standard review | Approved | None posted |
| Mar 24, 2023 | Supplement 22Labeling · Standard review | Approved | None posted |
| Mar 24, 2023 | Supplement 21Labeling · Standard review | Approved | None posted |
| Nov 3, 2020 | Supplement 17Labeling · Standard review | Approved | None posted |
| Nov 3, 2020 | Supplement 16Labeling · Standard review | Approved | None posted |
| Nov 3, 2020 | Supplement 15Labeling · Standard review | Approved | None posted |
| Nov 3, 2020 | Supplement 14Labeling · Standard review | Approved | None posted |
| Nov 3, 2020 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 1, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 19, 2014 | Supplement 10Labeling · Standard review | Approved | None posted |
| Sep 19, 2014 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 19, 2014 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 19, 2014 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 19, 2012 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 28, 2010 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters